By Dave Sebastian

 

Biogen Inc. said its Phase 2 study of vixotrigine, a drug being evaluated for the treatment of small fiber neuropathy, met its primary endpoint for the 200 milligram, twice-daily dose.

The study for the higher dose of 350 milligrams, twice daily didn't meet the primary endpoint, the company said Thursday, but it met the statistical significance in the patient global impression of change at week 12.

Small fiber neuropathy involves severe pain that begins in the feet or hands. Both doses were generally well tolerated by participants, the company said.

 

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

September 16, 2021 08:05 ET (12:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Biogen Charts.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Biogen Charts.